Steve-Felix Belinga, MD
Neurology · Fort Smith, ARNPI 1588817522
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $150,701 of the $183,306 with a category attached, or 82.2%. AbbVie accounts for 68.1% of it on its own, with 57 other manufacturers making up the rest. Reporting peaked in 2021 at $93,670 and has fallen 95.4% since, to $4,324 in 2025. Among neurology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,366 payments — averaging $134.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$125K
- Biohaven Pharmaceuticals, Inc.$23K
- Biohaven Pharmaceutical Holding Company Ltd.$11K
- Novartis$2K
- Livanova USA, Inc.$2K
- Abbott$2K
- plus $19K from 52 others
Across 29 payments — averaging $21,641 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$521K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$82K
- Biohaven Pharmaceutical Holding Company Ltd.$16K
- Pfizer$9K
What the payments were for
- Consulting fees$1500%
- Speaking & faculty fees$150,70182%
- Travel & lodging$8,4405%
- Food & beverage$23,78613%
- Education$2290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$112,366
- NURTEC ODT$32,751
- QULIPTA$12,343
- VNS Therapy$1,711
- INFINITY$1,664
- OXTELLAR XR$1,500
- XCOPRI$488
- INGREZZA$373
- NOURIANZ$367
- GOCOVRI$319
- ADLARITY$180
- TYSABRI$150
- OCREVUS$125
- RYTARY$125
- Mavenclad$125
- Filspari$125
- VYEPTI$125
- MAYZENT$115
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$112
- ZEPOSIA$108
How this compares
$183,306 in reported general payments places this provider in the 95th percentile of 93 neurology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 118 | $1,456,333 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $473,292 |
| Kesimpta PenOfatumumab | 48 | $463,353 |
| AustedoDeutetrabenazine | 18 | $249,350 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $146,623 |
| Nurtec OdtRimegepant Sulfate | 88 | $138,532 |
| BriviactBrivaracetam | 90 | $126,749 |
| Emgality PenGalcanezumab-Gnlm | 147 | $112,617 |
| IngrezzaValbenazine Tosylate | 11 | $87,590 |
| UbrelvyUbrogepant | 48 | $56,002 |
| GlatopaGlatiramer Acetate | 12 | $49,527 |
| FycompaPerampanel | 36 | $43,243 |
| QuliptaAtogepant | 40 | $43,073 |
| NayzilamMidazolam | 29 | $35,299 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $28,970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $790 | $611,824101 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $721 | $249,35018 claims |
| UCB, Inc.Briviact, Nayzilam | $832 | $162,049119 claims |
| AbbVieUbrelvy, Qulipta, Botox | $124,910 | $116,188101 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $953 | $87,59011 claims |
| Eisai Inc.Fycompa | $604 | $43,24336 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $539 | $25,39317 claims |
| SK Life Science, Inc.Xcopri | $1,675 | $23,41016 claims |
| Upsher-smith Laboratories LLCTopiramate | $454 | $1,936225 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $389 | $1,84127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 neurology providers in Arkansas.
Other neurology in Fort Smith
- William KnubleyFort Smith$26K
- Tonya PhillipsFort Smith$17K
- Janice KeatingFort Smith$16K
- Satish GaddamFort Smith$14K
- Vasile PopaFort Smith$8K
- John KareusFort Smith$3K
- Jon GustafsonFort Smith$2K
- Pradeep KumbhamFort Smith$2K
- Kathryn ChenaultSherwood$532K
- Michael MorseFayetteville$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.